Immunoglobulin A nephropathy (IgAN) remains a leading cause of chronic kidney disease and kidney failure globally. While standard treatments primarily focus on supportive care, clinicians increasingly seek targeted biological therapies to halt disease progression. Recent research highlights the potential of belimumab for IgA nephropathy as a promising treatment option. Specifically, a retrospective cohort study from Tongji Hospital in China evaluated the drug's effectiveness and safety between July 2020 and June 2024.

Clinical Outcomes of Belimumab for IgA Nephropathy

The study included 69 patients treated with belimumab and 137 propensity score-matched controls receiving standard therapy. Researchers defined the primary outcome as proteinuria remission, which involves a significant reduction in 24-hour urinary protein excretion. Consequently, the results showed marked improvements in the belimumab group compared to those receiving standard care alone. Furthermore, the safety profile of the medication remained consistent with its established use in lupus nephritis, with no unexpected adverse events reported.

Belimumab functions by targeting and inhibiting the B lymphocyte stimulator (BLyS). This protein plays a critical role in B-cell survival and the production of galactose-deficient IgA1, a key pathogen in IgAN. Because the disease's pathogenesis involves these specific immune complexes, inhibiting BLyS can potentially stabilize kidney function. Therefore, this real-world evidence supports expanding the clinical application of belimumab beyond its traditional use in systemic lupus erythematosus.

In addition, physicians in India should note that IgAN is highly prevalent and often progresses rapidly without intensive management. Although current international guidelines emphasize renin-angiotensin system blockade, they also encourage exploring therapies that target the underlying immune mechanisms. Consequently, this study provides a crucial foundation for future randomized controlled trials in diverse patient populations. Moreover, these findings suggest that adding belimumab to standard regimens might offer a strategic advantage in reducing long-term kidney damage.

Frequently Asked Questions

How does belimumab work for IgA nephropathy?

Belimumab is a monoclonal antibody that inhibits the B lymphocyte stimulator (BLyS). By blocking this protein, the drug reduces the survival of B cells and the production of abnormal IgA antibodies that cause kidney inflammation.

What were the primary findings of the Tongji Hospital study?

The study found that patients treated with belimumab achieved higher rates of proteinuria remission compared to matched controls receiving standard therapy. Additionally, the drug maintained a favorable safety profile throughout the four-year observation period.

Is belimumab currently recommended in clinical guidelines?

While belimumab is widely approved for lupus nephritis, its use in IgA nephropathy is currently supported by emerging real-world evidence and phase II trials. Clinicians often consider it as a targeted approach for patients who do not respond sufficiently to standard supportive care.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship between the reader and the author. Always consult a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

Wu M et al. Efficacy and safety of belimumab in IgA nephropathy: real-world evidence. Nephrol Dial Transplant. 2026 Mar 23. doi: undefined. PMID: 41871364.

Ma Y et al. Efficacy and safety of belimumab in refractory and newly diagnosed active lupus nephritis patients: a real-world observational study. Clin Kidney J. 2025 May 15;18(5):sfaf103.

Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2024 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN). Kidney Int. 2024.